Health Sciences Campus

Lorita Rebellato-deVente, Ph.D.

Lorita Rebellato-deVente


Department of Pathology
Brody School of Medicine
Brody Building, 7S10
Mail Stop 642
600 Moye Boulevard
Greenville, NC 27834

Office: 252-744-5007
Fax: 252-744-1889


Doctorate: East Carolina University, Greenville, NC, Ph.D. (Microbiology/Immunology)
Graduate: East Carolina University, Greenville, NC, M.S. (Biology)
Undergraduate: Federal University of Paraná, Curitiba, Paraná- Brazil, B.S. (Pharmacy and Biochemistry)

Board Certification

American Board of Histocompatibility and Immunogenetics

Clinical Interests

Histocompatibility testing and transplantation

Research Interests

  • Transplant immunobiology
  • Post-transplant monitoring
  • Donor-specific hyporesponsiveness
  • Cytokine gene polymorphisms
  • Xenotransplantation
  • HLA and disease associations


  • Taniguchi M, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, Catrou PG, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, and Terasaki PI. (2013)  "Higher Risk of Kidney Graft Failure in the Presence of Anti-Angiotensin II Type 1 Receptor Antibodies",  American Journal of Transplantation. 13:2577-2589.
  • Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sakaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC and Terasaki PI. (2013) "The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes", Transplantation 95 (9):1-7.
  • Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Bolin, Kendrick WT, Kendrick, Haisch CE, Harland RC, and Terasaki PI. (2013) "Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allograft", Transplantation 95 (3): 410-417.
  • Rebellato LM, Everly MJ, Haisch CE, Ozawa M, Briley KP, Parker K, Catrou PG,  Bolin P, Kendrick WT, Kendrick SA, and Harland RC. (2012) " A Report of the Epidemiology of De Novo Donor-Specific Anti-HLA Antibodies (DSA) in "Low-Risk" Renal Transplant Recipients",  Clinical Transplants 2011; 337-340.
  • Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE,  and  Terasaki PI. (2010) "Beyond Histology: Lowering HLA Antibody to Improve Renal Allograft Survival in Acute Rejection", Transplantation 89 (8):962-967.
  • Rebellato LM, Ozawa M, Verbanac KM, Catrou P, Haisch CE, and Terasaki PI. (2007) "Clinical and Anti-HLA Antibody Profile of Nine Renal Transplant Recipients with Failed Grafts: Donor-specific and Non-Donor-Specific Antibody Development", Clinical Transplants 2006: 241-253. 
  • Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C, and Rebellato L. (2007) "Extremely High Association Between Appearance of HLA antibodies and Failure of Kidney Grafts in a 5-year Longitudinal Study",  American Journal of Transplantation 7(4): 864-871. 
  • Cai J, Terasaki PI, Mao Q, Pham T, El-Awar N, Lee JH, and Rebellato L. (2006) "Development of Nondonor-Specific HLA-DR Antibodies in Allograft Recipients is Associated with Shared Epitopes with Mismatched Donor DR Antigens",  American Journal of Transplantation 6 (12): 2947-2954. 
  • Rebellato LM, Verbanac KM, and Haisch CE. (2005) " The Current Status of Xenotransplantation", Current Surgery 62(5):481-488. 
  • Rebellato LM, Arnold AN, Bozik KM, and Haisch CE. (2002) "HLA Matching and the United Network for Organ Sharing (UNOS) Allocation System: Impact of HLA Matching on African American Recipients of Cadaveric Kidney Transplants", Transplantation 74(11): 1634-1636.